KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Immunogenicity and safety of DS-5670d, an omicron XBB.1.5-targeting COVID-19 mRNA vaccine: A phase 3, randomized, active-controlled study.

Ami Kawamoto, Masahiro Hashida, Katsuyasu Ishida, Kei Furihata, Aisaku Ota, Kaori Takahashi, Sachiko Sakakibara, Takashi Nakano, Fumihiko Takeshita

PLoS Med 22(10) e1004499

PMID41082550
PMCIDPMC12517495
DOI10.1371/journal.pmed.1004499
发表日期2025-10-13
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

BACKGROUND: DS-5670d is a monovalent lipid nanoparticle-messenger ribonucleic acid vaccine against severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), containing an omicron XBB.1.5-derived antigen. This phase 3 non-inferiority study assessed the immunogenicity and safety of a single dose of DS-5670d according to participant immune status. METHODS AND FINDINGS: Participants aged ≥12 years were stratified according to their history of both prior SARS-CoV-2 infection plus prior coronavirus disease 2019 vaccination (subpopulation A), prior infection only (subpopulation B), prior vaccination only (subpopulation C), or no history of either infection or vaccination (subpopulation D), and randomly assigned (1:1) to receive DS-5670d or monovalent BNT162b2 omicron XBB.1.5. The primary efficacy endpoint was geometric mean titer (GMT) of blood neutralizing activity against SARS-CoV-2 (omicron XBB.1.5) and seroresponse rate at day 29 after study vaccine administration in the combined ABC subpopulations (DS-5670d, n = 362 versus BNT162b2, n = 363). Prespecified non-inferiority margins required that the lower limit of the 95% confidence interval (CI) exceeded 0.67 for the GMT ratio and -10% for the difference in seroresponse. The adjusted GMT ratio was 1.218 (95% confidence interval [CI], 1.059, 1.401). Seroresponse rates were 87.3% (DS-5670d) and 82.9% (BNT162b2); adjusted difference 4.5% (95% CI, -0.70, 9.71). Both results exceeded the non-inferiority margins and the study met the primary endpoint. Immunogenicity data in the overall ABCD population also met non-inferiority criteria. There were no apparent immunogenicity differences according to age or sex, and analyses suggested that even unvaccinated persons achieved an adequate immune response following a single dose of DS-5670d. There were no major differences in the incidence or severity of adverse events between the study vaccination groups. The main study limitation was the short duration of follow-up. CONCLUSIONS: A single dose of DS-5670d was immunogenically non-inferior to BNT162b2 and acceptably safe in persons with or without a history of prior infection and/or vaccination. Trial registration Japan Registry of Clinical Trials (jRCT2031230424).

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Fig 3

Fig 3. Incidence of investigator-confirmed COVID-19 (efficacy-evaluable PPS). CI, confidence interval; PPS, per protocol set.

Panel_1

Incidence of investigator-confirmed COVID-19

Fig 3 · Panel Panel_1

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel Panel_1 是同一 Fig 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig 1Fig 1. (A) Study design and (B) CONSORT flow diagram of participant disposition through the study. aThe efficacy FAS and safety analysis sets were identical. bIncluded 147 (37.4%) in subpopulation A; 67 (17.0%) in subpopulation B; 163 (41.5%) in subpopulation C, and 16 (4.1%) in subpopulation D. cIncluded 139 (36.2%) in subpopulation A; 66 (17.2%) in subpopulation B; 167 (43.5%) in subpopulation C, and 12 (3.1%) in subpopulation D. dCombined ABCD subpopulation. FAS, full analysis set; PPS, per protocol set; R, random assignment.
非 KM Figure
Fig 2Fig 2. Forest plot of immunogenicity against SARS-CoV-2 (omicron XBB.1.5.6) at day 29 by subgroup for (A) observed GMT ratio of blood neutralizing activitya and (B) seroresponse rateb (immunogenicity-evaluable PPS). a The observed GMT ratio (DS-5670d vs. BNT162b2 omicron XBB.1.5) and 95% CI were calculated based on the Student’s distribution of the mean difference in the log-transformed values then back transformed to the original scale for presentation. b The seroresponse rate observed difference (DS-5670d – BNT162b2 omicron XBB.1.5) and 95% CI were calculated based on the Newcombe-Wilson score method. CI, confidence interval; PPS, per protocol set; SARS-CoV-2, severe acute respiratory syndrome-coronavirus-2.
非 KM Figure
Fig 4Fig 4. Solicited AEs (A) injection site AEs; (B) systemic AEs (safety analysis set). AE, adverse event.
非 KM Figure